Damora Therapeutics, Inc. (DMRA)
DMRANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$24.73
+0.5800 (+2.40%) today
Regular session, Nov 11, 10:01 AM ET
- Market cap
- $1.53bn
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $23.87 to $25.07
- 52-week range
- $15.00 to $38.33
- Average volume
- 602.7k
- Previous close
- $24.15
Analysts
8 coveringBuy8 buy, 0 hold, 0 sell
Targets a year out average $46.67, +88.7% from here
Earnings
next estimate $-0.4900Next report
Mar 2026
-195.2%
Jun 2026
-2.6%
Sep 2026
+23.1%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$201.70m | -$30.81m | -$34.99m | -$36.86m |
| Net income | -$200.74m | -$27.78m | -$31.17m | -$31.99m |
News
8 latest- Damora Therapeutics Grants Inducement Awards To Three New Employees RTTNews · Sep 3, 2026
- Damora Posts Wider Loss In Q2 On Increased Expenses; Expects Cash Runway Into 2029 RTTNews · Aug 11, 2026
- Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% SurgeThe Motley Fool · May 30, 2026
- Wedbush Initiates Coverage of Damora Therapeutics (DMRA) with Outperform RecommendationFintel · May 28, 2026
- What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?Zacks · Apr 20, 2026
- How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%Zacks · Apr 10, 2026
- Damora Therapeutics Posts FY25 Results, Advances MutCALR Blood-Disorder Pipeline RTTNews · Mar 20, 2026
- UBS Initiates Coverage of Galecto (GLTO) with Buy RecommendationFintel · Feb 17, 2026
The company
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Europe
- Website
- damoratx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.